key: cord-0810620-q15vrejm authors: Beken, Burcin; Ozturk, Gokcen Kartal; Aygun, Fatma Deniz; Aydogmus, Cigdem; Akar, Himmet Haluk title: Asthma and allergic diseases are not risk factors for hospitalization in children with COVID-19 date: 2021-01-23 journal: Ann Allergy Asthma Immunol DOI: 10.1016/j.anai.2021.01.018 sha: a9404b0c6d1490b2391a096b8de3589b82087b26 doc_id: 810620 cord_uid: q15vrejm BACKGROUND: COVID-19 emerged as a pandemic toward the end of 2019, causing large numbers of people to become infected and die. OBJECTIVE: To determine whether allergic diseases are a risk factor for hospitalization in COVID-19. METHODS: We conducted a study including 107 pediatric patients after COVID-19 recovery. ISAAC Phase 3 questionnaires were distributed together with a detailed history of environmental factors and an allergic evaluation including skin prick tests, specific IgE tests, and spirometry. We investigated the prevalence of allergic diseases and evaluated the factors associated with hospitalization in COVID-19. RESULTS: Sixty-one (57%) patients were hospitalized and 46 (43%) patients were followed closely in the outpatient clinic. The prevalence of allergic rhinitis (AR ), recurrent wheezing, atopic dermatitis (AD), and asthma was 10.3%, 5.5%, 4.7%, and 3.7%, respectively, within the whole study population. While having asthma ± AR, AD, and passive tobacco exposure were not found to be related to hospitalization due to COVID-19, having a pet at home was found to be decreased risk of hospitalization (OR: 0.191, 95% CI: 0.047-0.779, p = 0.021). Spirometry tests revealed a higher FEV1/FVC ratio and a PEF reversibility in hospitalized patients compared to nonhospitalized ones (p = 0.023 and p = 0.003, respectively). CONCLUSION: Asthma and allergic diseases do not appear to be risk factors for hospitalization due to COVID-19 in children, and having a pet at home can be a protective effect. Pulmonary function testing seems to be important for monitoring lung damage following COVID-19. Objective: To determine whether allergic diseases are a risk factor for hospitalization in COVID-19. Methods: We conducted a study including 107 pediatric patients after COVID-19 recovery. ISAAC Phase 3 questionnaires were distributed together with a detailed history of environmental factors and an allergic evaluation including skin prick tests, specific IgE tests, and spirometry. We investigated the prevalence of allergic diseases and evaluated the factors associated with hospitalization in COVID-19. Results: Sixty-one (57%) patients were hospitalized and 46 (43%) patients were followed closely in the outpatient clinic. The prevalence of allergic rhinitis (AR ), recurrent wheezing, atopic dermatitis (AD), and asthma was 10.3%, 5.5%, 4.7%, and 3.7%, respectively, within the whole study population. While having asthma ± AR, AD, and passive tobacco exposure were not found to be related to hospitalization due to COVID-19, having a pet at home was found to be decreased risk of hospitalization (OR: 0.191, 95% CI: 0.047-0.779, p = 0.021). Spirometry tests revealed a higher FEV1/FVC ratio and a PEF reversibility in hospitalized patients compared to nonhospitalized ones (p = 0.023 and p = 0.003, respectively). Conclusion: Asthma and allergic diseases do not appear to be risk factors for hospitalization due to COVID-19 in children, and having a pet at home can be a protective effect. Pulmonary function testing seems to be important for monitoring lung damage following COVID-19. The largest prevalence studies to date have been limited to a description of the number of 25 cases by age, so it remains unclear whether childhood asthma and allergic diseases are 26 associated with COVID-19 risk and severity. Furthermore, the allergic diseases reported in 27 these studies were based on patient declarations or medical records. In this study, we aimed 28 to investigate the frequency of allergic diseases in pediatric COVID-19 patients based on 29 clinical and laboratory evaluation and examine whether allergic diseases are a risk factor for 30 hospitalization. 33 The study was conducted in children aged between 0 and 18 years old admitted to the 34 hospital with COVID symptoms between March 15 and May 31, 2020. Our hospital is a 35 tertiary reference hospital in Istanbul, Turkey and our emergency department has a COVID- 36 19 outpatient clinic where all suspected cases (not only symptomatic but also asymptomatic 37 individuals who have contact with a patient with COVID-19 PCR positivity) are evaluated. 38 The study was approved by the local ethics committee (No: KAEK/2020.08.189). 39 The study population included the following: Written informed consents were taken from the patients and their parents before the tests. An asthma diagnosis was based on respiratory symptoms typical of asthma + documentation 90 of variable airflow limitation by pulmonary function testing (PFT) (FEV1 < 80%, FEV1/FVC 91 < 80%, and > 12% reversibility of FEV1) for children > 5 years old 15 and based on modified 92 asthma predictive index for children ≤ 5 years old. 16 A diagnosis of allergic rhinitis (AR) was 93 made with two or more nasal symptoms (i.e. congestion, rhinorrhea, sneezing, and itching) 94 persisting for at least one hour a day for more than two weeks + aeroallergen sensitization 95 shown by SPT and/or allergen-specific IgE. 17 The hospitalized and non-hospitalized patient characteristics during COVID-19 are shown in 119 Table 1 . Fifteen (14%) patients indicated ever having asthma, eight (7.5%) patients ever having hay 130 fever, and six (5.6%) patients ever having eczema. There was no difference in terms of 131 allergic symptoms based on the ISAAC questionnaire between the hospitalized and non-132 hospitalized patients (see Table 2 ). Evaluation of allergic diseases 135 The number of patients diagnosed as allergic rhinitis, asthma, AD, and episodic wheezing 136 after allergy evaluation (allergic symptoms, SPT / sIgE and spirometry) were 11 (10.3%), 7 137 (6.5%), 5 (4.7%), and 4 (3.7%) respectively. Aerollergen sensitization was found in 22 138 (22.2%) patients, with the most common sensitized allergen being Dermatophagoides sp. 139 (n=12) followed by grass mix (n=8), weed mix (n=3), trees mix (n=3), dog (n=2), cat (n=1), 140 and Alternaria alternata (n=1). Food allergen sensitization was found in two (1.9%) patients 141 without any symptoms related to food allergy. The distribution of allergic diseases between 142 hospitalized and non-hospitalized patients is seen in Table 3 . Table 3 . 155 Fourteen (13.1%) patients described pulmonary symptoms, such as ongoing cough, shortness 156 of breath, chest pain, and exercise dyspnea after SARS-CoV-2 infection, with nine of these IgE levels and eosinophil counts either (p = 0.999 and p = 0.934, respectively) (see Table 3 ). Table 4 ). Having asthma ± AR was also not found to be associated with prolonged hospitalization 178 (median: 8 days (IQR: 5.5-9 days) for patients with asthma ± AR vs. median: 8 days (IQR: 6-179 10 days) for patients without asthma ± AR) (p = 0.882). It is now well established that age, a history of smoking, and certain comorbidities, including 183 hypertension, diabetes, obesity, and coronary artery disease, pose a higher risk for severe 184 COVID-19, 19-21 but the context of asthma is controversial. There is scarcely any data on 185 whether childhood asthma constitutes a risk factor for SARS-CoV-2 infection or 186 hospitalization due to COVID-19. In our study population, while the ISAAC questionnaire-187 based asthma prevalence was 14%, the physician-diagnosed asthma prevalence was 6.5%, 188 which is lower than the general prevalence of asthma in Turkish children (6.9% in 2003 22 and 189 17.8% in 2006). 23 It was a limitation for us not having a spirometry before the Sars-COV-2 190 infection, but it seems impossible to design such a study because of the impossibility of predicting who will get COVID. There is also a possibility of a post-COVID bronchial 192 reactivity, however, we made the asthma diagnosis not just with spirometry but also with 193 asthma-related symptoms before they got COVID-19 and allergic evaluation. The prevalence of asthma among adult COVID-19 patients shows marked regional 195 differences, with an incidence lower than the general population in China (0.9%), 24 Italy 196 (1.96% and 1.92%), 25 Sweden (1.8% and 2.6%), 26 Russia (1.8%), 27 and Brazil (1.5%), 28 but a 197 higher incidence in Spain (5.2%), 29 Ireland (8.8%), 30 the UK (17.9%), 31 and the USA (7.4% 198 14%). 32, 33 Prevalence data on asthma among pediatric COVID-19 patients are quite scarce. In our study, AR was detected in 10.3% of our patients and was not found to be related to the 213 hospitalization in COVID-19 patients. Similarly, Chibba et al 33 found an 11.6% prevalence of 214 epithelial cells but also in nasal epithelial cells. 37 Considering the studies done so far, AR 217 does not appear to be a risk factor for COVID-19 either. 218 We investigated factors affecting hospitalization in COVID-19 patients; none of the allergic 219 conditions were found to be a risk factor for hospitalization. Similar to our finding, a previous 220 epidemiological study of 1526 patients from the USA reported that 14% of patients with 221 COVID-19 had asthma, but the presence of asthma and the use of inhaled and/or systemic 222 corticosteroids were not found to be risk factors for hospitalization. 6 Rosenthal et al. 38 223 retrospectively evaluated 727 COVID-19 patients (median age: 49 years), and asthma was 224 not found to be associated with hospitalization, intensive care unit (ICU) admission, or death. However, intubation was found to be two-fold higher among asthmatics compared to non-226 asthmatics, without a significant difference in duration or hospitalization. 38 It has been recently reported that patients with COVID-19 pneumonia have residual 228 abnormalities, most commonly ground-glass opacity in chest CT scans during discharge, 229 which may affect pulmonary functions. 39 However, few studies have performed PFT for Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 WHO Coronavirus Disease (COVID-19) Dashboard Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study The influence of asthma control on the severity of virus-induced asthma exacerbations Coronavirus Disease 2019 in Children -United States COVID-19) People at increased risk Managing childhood allergies and immunodeficiencies during respiratory virus epidemics -The 2020 COVID-19 pandemic: A statement from the EAACI-section on pediatrics Asthma and COVID-19 in children: A systematic review and call for data Impact of the COVID-19 pandemic in children with allergic asthma Chest CT manifestations of new coronavirus disease 2019 (COVID-19): a pictorial review Management of Pediatric Communityacquired Bacterial Pneumonia The international study of asthma and allergies in childhood (ISAAC): phase three rationale and methods Practical considerations for spirometry during the COVID-19 outbreak: Literature review and insights The Prevention of Early Asthma in Kids study: design, rationale and methods for the Childhood Asthma Research and Education network Paediatric rhinitis: position paper of the European Academy of Allergy and Clinical Immunology Diagnostic features of atopic dermatitis Predicting a worse COVID-19 outcome Obesity -a risk factor for increased COVID-19 prevalence, severity and lethality (Review) Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients Prevalence of asthmatic phenotypes and bronchial hyperresponsiveness in Turkish schoolchildren: an International Study of Asthma and Allergies in Childhood (ISAAC) phase 2 study Rising trend of asthma prevalence among Turkish schoolchildren (ISAAC phases I and III) Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan Asthmatic patients in COVID-19 outbreak: Few cases despite many cases Burden and prevalence of prognostic factors for severe COVID-19 in Sweden Low prevalence of bronchial asthma and chronic obstructive lung disease among intensive care unit patients with COVID-19 Adults at high-risk of severe coronavirus disease-2019 (Covid-19) in Brazil A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe Prevalence of comorbid asthma in COVID-19 patients Associations with covid-19 hospitalisation amongst 406,793 adults. The UK Biobank Prospective Cohort Study Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19 SARS-CoV-2 testing and outcomes in the first 30 days after the first case of COVID-19 at an Australian children's hospital Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status Pediatric asthma and COVID-19: The known, the unknown, and the controversial Expression of ACE2 in airways: Implication for COVID-19 risk and disease management in patients with chronic inflammatory respiratory diseases Asthma Is Associated with Increased Risk of Intubation but Not Hospitalization or Death in COVID-19 Temporal Changes of CT Findings in 90 Patients with COVID-19 Pneumonia: A Longitudinal Study Pulmonary function in patients surviving to COVID-19 pneumonia Abnormal pulmonary function in COVID-19 patients at time of hospital discharge Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study Bronchial inflammation and the common cold: a comparison of atopic and non-atopic individuals Long-term respiratory follow-up of H1N1 Laboratory evaluation Hemoglobin (g/dL, median, IQR) Leucocyte count (cells/mm3, median, IQR) Platelet count (cells/mm3, median, IQR) Neutrophil count (cells/mm3, median Lymphocyte count (cells/mm3, median CRP (g/dL, median, IQR)